GlassScriptPhysician profile
Erica Barringer
NPI 1134175961
$3,266.27
in general payments reported to CMS, 2019-2025
34 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $817 · 2020: $241 · 2021: $352 · 2022: $366 · 2023: $306 · 2024: $603 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $857.12 | 2021-2025 | Vraylar |
| Novartis Pharmaceuticals Corporation | $723.10 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $317.65 | 2020-2025 | Airsupra, Farxiga, Lokelma |
| Novo Nordisk INC | $190.19 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $186.45 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $91.10 | 2022-2024 | Mounjaro, Jardiance |
| Amgen INC. | $82.74 | 2019-2025 | Otezla, Repatha |
| Amarin Pharma, INC. | $72.42 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.49 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $62.68 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $53.62 | 2019 | |
| Alexion Pharmaceuticals, INC. | $46.09 | 2022-2024 | Soliris |
| E.R. Squibb & Sons, L.L.C. | $41.30 | 2022-2024 | Camzyos |
| Biohaven Pharmaceutical Holding Company LTD. | $38.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.46 | 2019-2024 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $37.84 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $36.68 | 2021-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Shire North American Group INC | $29.34 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.90 | 2022 | |
| Pfizer INC. | $28.43 | 2021 | |
| Avanir Pharmaceuticals, INC. | $25.46 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.45 | 2023 | Nuzyra |
| Daiichi Sankyo INC. | $21.33 | 2022 | |
| Hologic Sales and Service, LLC | $18.82 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $17.92 | 2021 | |
| Exact Sciences Corporation | $17.47 | 2024 | Cologuard Collection Kit |
| Abbott Laboratories | $17.19 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.11 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.85 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $13.64 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.54 | 2021 | |
| Therapeuticsmd, INC. | $12.87 | 2019 | |
| Esperion Therapeutics, INC. | $12.77 | 2021 | |
| Melinta Therapeutics, LLC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Barringer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.